Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target

Benzinga · 1d ago
Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.